Alpha-1 Antitrypsin Deficiency (AATD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Alpha-1 Antitrypsin Deficiency (AATD) is an autosomal codominant genetic condition that can result in serious lung disease in adults and/or liver disease at any age. AATD occurs when the blood is deficient in a protein called Alpha-1 antitrypsin, or AAT. The liver mainly produces AAT, which primarily protects the lungs from increased protease activity. The responsible gene, SERPINA1, is located on the long arm of chromosome 14 (14q31–32.3).

  • According to Thelansis disease modeling data and literature review estimated, ~78000 patients with AATD in the United States in the year 2020.

Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alpha-1 Antitrypsin Deficiency (AATD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Alpha-1 Antitrypsin Deficiency (AATD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Alpha-1 Antitrypsin Deficiency (AATD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Alpha-1 Antitrypsin Deficiency (AATD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033